{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:07:06Z","timestamp":1784279226567,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijrobp.2026.02.206","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:43:04Z","timestamp":1771000984000},"page":"1330-1337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estimation of Maximum Cumulative Administered Activity for Radiopharmaceuticals in Early Clinical Trials: Assessing Long-Term Toxicity Risks of 177Lu-DOTATATE"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1236","authenticated-orcid":false,"given":"Zufar","family":"Mulyukov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.02.206_bib0001","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl","key":"10.1016\/j.ijrobp.2026.02.206_bib0002","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0003","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl 1","key":"10.1016\/j.ijrobp.2026.02.206_bib0004","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose\u2013effect relationship","volume":"46","author":"Barone","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0005","first-page":"134","article-title":"Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy","volume":"48","author":"Konijnenberg","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0006","series-title":"Dosimetry for Radiopharmaceutical Therapy","first-page":"191","article-title":"Clinical radiobiological modeling for radiopharmaceutical therapy","author":"Sgouros","year":"2024"},{"issue":"suppl 3","key":"10.1016\/j.ijrobp.2026.02.206_bib0007","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62","author":"Wahl","year":"2021","journal-title":"J Nucl Med"},{"issue":"3 suppl","key":"10.1016\/j.ijrobp.2026.02.206_bib0008","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.ijrobp.2009.02.089","article-title":"Radiation-associated kidney injury","volume":"76","author":"Dawson","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0009","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00259-023-06559-9","article-title":"Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy","volume":"51","author":"Li","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0010","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0011","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","article-title":"MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response\u2014implications for radionuclide therapy","volume":"49","author":"Wessels","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0012","unstructured":"U.S. Food and Drug Administration. Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development. Draft Guidance for Industry. Updated August 18, 2025. Accessed August 29, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/oncology-therapeutic-radiopharmaceuticals-dosage-optimization-during-clinical-development"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0013","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0014","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0015","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0016","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00004032-200309000-00006","article-title":"Physical models and dose factors for use in internal dose assessment","volume":"85","author":"Stabin","year":"2003","journal-title":"Health Phys"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0017","first-page":"619","article-title":"Is the renal dosimetry for [90Y-DOTA0, Tyr3]octreotide accurate enough to predict thresholds for individual patients?","volume":"18","author":"Konijnenberg","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0019","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MNM.0000000000001198","article-title":"Nephrotoxicity\/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review","volume":"41","author":"Stolniceanu","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0021","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/444\/1\/012006","article-title":"Accuracy required and achievable in radiotherapy dosimetry: have modern technology and techniques changed our views?","volume":"444","author":"Thwaites","year":"2013","journal-title":"J Phys Conf Ser"},{"key":"10.1016\/j.ijrobp.2026.02.206_bib0022","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2967\/jnumed.123.267293","article-title":"An international study of factors affecting variability of dosimetry calculations, part 3: contribution from calculating absorbed dose from time-integrated activity","volume":"65","author":"Brosch-Lenz","year":"2024","journal-title":"J Nucl Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600386X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600386X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:26:51Z","timestamp":1784276811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162600386X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S036030162600386X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.02.206","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimation of Maximum Cumulative Administered Activity for Radiopharmaceuticals in Early Clinical Trials: Assessing Long-Term Toxicity Risks of 177Lu-DOTATATE","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.02.206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}